Cochrane · systematic review · CD014788
Gonadotropin‐releasing hormone analogues for endometriosis
Veth, VB, van de Kar, MMA, Duffy, JMN, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
19
current version
GRADE rated
16
No studies
3
Included studies
NR
No studies 3 · 15.8%Ungraded 0 · 0%Very low 11 · 57.9%Low 5 · 26.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
GnRHas compared to no treatment for relief of overall pain associated with endometriosis and its related adverse effects
Population: Women with endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No studies included for any outcomes GnRHas vs no treatment | no estimate extracted | NR | No studies |
GnRHas compared to placebo for relief of overall pain associated with endometriosis and its related adverse effects
Population: Women with endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relief of overall pain ‐ reported as pelvic pain ‐ 3 months GnRHas vs placebo | RR 2.14 [1.41, 3.24] | 1 study · 87 participants | Low |
Relief of overall pain ‐ reported as dysmenorrhoea ‐ 3 months GnRHas vs placebo | RR 2.25 [1.59, 3.16] | 1 study · 87 participants | Low |
Relief of overall pain ‐ reported as dyspareunia ‐ 3 months GnRHas vs placebo | RR 2.21 [1.39, 3.54] | 1 study · 87 participants | Low |
Relief of overall pain ‐ reported as pelvic tenderness scores‐ 3 months GnRHas vs placebo | RR 2.28 [1.48, 3.5] | 1 study · 87 participants | Low |
Relief of overall pain ‐ reported as pelvic induration scores ‐ 3 months GnRHas vs placebo | RR 1.07 [0.64, 1.79] | 1 study · 87 participants | Low |
GnRHas compared to analgesics for relief of overall pain associated with endometriosis and its related adverse effects
Population: Women with pain due to endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No studies included for any outcomes GnRHas vs analgesics | no estimate extracted | NR | No studies |
GnRHas compared to danazol for relief of overall pain associated with endometriosis and its related adverse effects
Population: Women with pain due to endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relief of overall pain ‐ reported as pelvic tenderness, partly resolved ‐ 6 months GnRHas vs danazol | RR 1.15 [0.49, 2.73] | 1 study · 41 participants | Very low |
Relief of overall pain ‐ reported as pelvic tenderness, complete resolved ‐ 6 months GnRHas vs danazol | RR 1.1 [0.67, 1.81] | 1 study · 41 participants | Very low |
Relief of overall pain ‐ 6 months GnRHas vs danazol | no estimate extracted | 1 study · 41 participants | Very low |
Relief of overall pain ‐ reported as pelvic pain ‐ 6 months GnRHas vs danazol | no estimate extracted | 1 study · 41 participants | Very low |
Relief of overall pain ‐ reported as dysmenorrhoea ‐ 6 months GnRHas vs danazol | no estimate extracted | 1 study · 41 participants | Very low |
Relief of overall pain ‐ reported as pelvic induration ‐ 6 months GnRHas vs danazol | no estimate extracted | 1 study · 41 participants | Very low |
Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months GnRHas vs danazol | no estimate extracted | 1 study · 41 participants | Very low |
GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis and its related adverse effects
Population: Women with pain due to endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No studies included with only low risk of bias GnRHas vs intra‐uterine progestogens device | no estimate extracted | NR | No studies |
Effect of GnRHas versus other hormonal treatment on bone mineral density
Population: Women with endometriosis, treated with GnRHas with effect on bone mineral density
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GnRHas vs gestrinone Percentage change values ‐ 6 months Effect of GnRHas vs other hormonal treatment on bone mineral density | no estimate extracted | 1 study · 41 participants | Very low |
GnRHas vs gestrinone Percentage change values ‐ 12 months Effect of GnRHas vs other hormonal treatment on bone mineral density | no estimate extracted | 1 study · 41 participants | Very low |
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Anterior‐posterior spine ‐ 12 months Effect of GnRHas vs other hormonal treatment on bone mineral density | no estimate extracted | 1 study · 43 participants | Very low |
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Lateral spine ‐ 12 months Effect of GnRHas vs other hormonal treatment on bone mineral density | no estimate extracted | 1 study · 43 participants | Very low |